Trials / Not Yet Recruiting
Not Yet RecruitingNCT07294300
A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of QLS2313 for Injection in Patients With Relapsed/Refractory Hematological Malignancies
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 124 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLS2313 | CD79b/CD3/CD20;first in human; subcutaneous injection |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2028-02-01
- Completion
- 2028-02-01
- First posted
- 2025-12-19
- Last updated
- 2025-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07294300. Inclusion in this directory is not an endorsement.